Endogenous innovations in the pharmaceutical industry

This paper addresses the creation of new products in the US pharmaceutical sector, during the second half of the 20th century. We indicate that the continuous increases in population, and thus in the market size of this sector, play a fundamental role in explaining the large creation of new drugs during that period. We also argue that population and market size can be endogenously determined through the impact of drugs over the mortality rate. Hence, these two effects reinforce each other, producing decrements in the mortality rate and increments in the stock of drugs over time. We obtained the set of new molecular entities approved by the FDA during the second half of the 20th century and we decomposed the data in a panel of 15 therapeutic categories over time. Using this data, we tested our hypotheses using different econometric methods. The results support the hypothesis and are consistent across methods.

Rodrigo A. CerdaEmail: